Buccal absorption of midazolam: Pharmacokinetics and EEG pharmacodynamics

88Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose: To determine whether buccal/sublingual administration of midazolam (MDL) would lead to detectable venous concentrations and EEG changes in 10 healthy volunteers. Methods: The study consisted of an open- label and a double-blind phases. Subjects held 10 mg MDL in 2 ml peppermint- flavored fluid or peppermint-flavored placebo in their mouth fOr 5 min and then spat it out. Cardiorespiratory and EEG monitoring was performed in all subjects. Results: Venous MDL concentrations measured on 10 occasions from 5 to 600 main after administration showed a rapid increase for the first 20-30 min. However, changes in the 8-to 30-Hz frequencies identified by spectral analysis of the EEG showed changes in ≤5-10 min in test but not in control subjects-more rapid than were expected from the venous absorption data. There were no significant adverse effects. Conclusions: Our data provide direct evidence of the speed of cerebral effect of a drag. Our results suggest that the buccal/sublingual route of administration should be tested in emergency treatment of seizures as an alternative to the rectal route, over which it has clear practical advantages.

Cite

CITATION STYLE

APA

Scott, R. C., Besag, F. M. C., Boyd, S. G., Berry, D., & Neville, B. G. R. (1998). Buccal absorption of midazolam: Pharmacokinetics and EEG pharmacodynamics. Epilepsia, 39(3), 290–294. https://doi.org/10.1111/j.1528-1157.1998.tb01375.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free